Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or ...

Merck (NYSE:MRK) has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite ...

Merck & Co. has won approval from the European Commission of its Capvaxive pneumococcal disease vaccine for adults. The Rahway, N.J., drugmaker on Wednesday said the approval covers the 21-valent ...

US pharma giant Merck & Co (NYSE: MRK) today announced that the European Commission (EC) has approved Capvaxive (Pneumococcal ...

Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the latter is comfortably in front at the moment with its Prevnar franchise, Merck has multiple ...

In an attempt to strike a pitch-perfect tone with Generation X, Pfizer has recruited Elizabeth Banks as the face of a new ...

Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent ...

Merck’s new 21-valent pneumococcal conjugate vaccine, Capvaxive, and Winrevair have the potential to generate significant revenues for Merck over the long term. Both the products are witnessing ...

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a 225,000-square-foot addition to the company’s existing campus off Old Oxford Road.